E-ERAD-135 - Praziquantel mode of action and resistance

Released on 13 May 2013, last updated on 18 May 2016
Dugesia japonica, Schistosoma mansoni
Samples (324)
Protocols (2)
This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/The drug Praziquantel is the most commonly used drug for parasitic flatworms. It is currently being increasingly used in mass drug administration programmes, raising concerns over whether resistance will develop. Although widely used, its mode of action was until very recently uncertain. This study will investigate the praziquantel mode of action and resistance by sequencing the transcriptomes of Dugesia japonica and different stages and strains of S. mansoni.
Experiment type
RNA-seq of coding RNA 
Exp. designProtocolsVariablesProcessedSeq. reads
Investigation descriptionE-ERAD-135.idf.txt
Sample and data relationshipE-ERAD-135.sdrf.txt